Dual inhibition of oncogenic targets for B-cell malignancies

[Comment] 

Effective treatment options for patients with relapsed and refractory lymphoma and multiple myeloma remain an area of unmet medical need, despite recent advances in both diseases. In The Lancet Oncology, Anas Younes and colleagues1 present the results of a phase 1 safety and dose escalation study of CUDC-907—a first-in-class, oral, dual inhibitor of histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K)—in patients with advanced refractory lymphoma and multiple myeloma.2–5 The study was a first-in-man, multicentre trial in which CUDC-907 was orally administered in the standard 3+3 dose escalation design at four different dosing schedules, enrolled sequentially: first daily, then twice or thrice weekly, and finally a 5 days on 2 days off (5/2) schedule, in 21 day cycles.

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1MGvWFb
via IFTTT